At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Bevonesceindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/2 Trial of ALM-488 in Patients Undergoing Head & Neck Surgery
In Brief
A Phase 2 clinical trial evaluating Bevonescein for Parotid Neoplasm and 5 related conditions. Completed, enrolled 27 participants across 3 sites.
Detailed Summary
Bevonescein to Highlight Nerves in Patients Undergoing Head \& Neck Surgery
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParotid Neoplasm, Thyroid Neoplasms, Head and Neck Neoplasms, Surgery, Nerve Injury, Imaging
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJun 2020
Primary CompletionJun 2021
Study CompletionFeb 2022
TodayJul 2026
First PostedJun 9, 2020
Enrollment StartJun 18, 2020
Primary CompletionJun 25, 2021
Study CompletionFeb 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 6.1 years ago
Interventions
Bevonesceindrug
Bevonescein Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.